Lanean...
Effect of OROS® controlled-release delivery on the pharmacokinetics and pharmacodynamics of oxybutynin chloride
AIMS: Dry mouth is a common side-effect seen with immediate-release oxybutynin (IR-Oxy). Ditropan XL® [(Oxy-XL), a controlled-release formulation of oxybutynin chloride, is a once-daily oral dosage form that incorporates the OROS® technology. Dry mouth as the pharmacodynamic measure was compared bet...
Gorde:
| Egile Nagusiak: | , , |
|---|---|
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Blackwell Science Inc
2001
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2014596/ https://ncbi.nlm.nih.gov/pubmed/11678784 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1046/j.0306-5251.2001.01463.x |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|